Optimal Evaluation to Reduce Cardiovascular Imaging Testing
Launched by TIANJIN CHEST HOSPITAL · Dec 5, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
The OPERATE study is a clinical trial designed to find better ways to evaluate patients with stable chest pain that might be related to chronic coronary syndrome (CCS). This trial will compare two different strategies to help doctors identify patients who are at low risk and may not need further heart imaging tests, specifically coronary computed tomography angiography (CCTA). By doing this, the study aims to reduce unnecessary tests and focus on what is best for the patient's health.
To participate in this trial, individuals should be at least 30 years old and experiencing stable chest pain suggestive of CCS, without a history of coronary artery disease. Participants will be randomly assigned to one of the two diagnostic strategies being studied and will have regular follow-ups during the trial. It’s important to note that those with certain medical conditions, recent heart tests, or specific health issues may not be eligible. This study is currently recruiting participants, and it offers an opportunity to contribute to improving heart health evaluations in everyday medical practice.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • 1. SCP or equivalenta suggestive of CCS and clinically stability
- • 2. No history of CAD (prior myocardial infarction, CR or any CAD documented by previous CIT)
- • 3. Age ≥30 years
- • 4. Willing and able to provide informed consent
- • Exclusion criteria
- • 1. Prior CIT within 1 year prior to randomization
- • 2. Clinically instability (e.g. cardiogenic shock, ACS, severe arrhythmias or NYHA III or IV heart failure)
- • 3. Non-sinus rhythm
- • 4. Concomitant participation in another clinical trial
- • 5. Complex structural heart disease
- • 6. Non-cardiac illness with life expectancy \< 2 years
- • 7. Allergy to iodinated contrast agent
- • 8. Estimated glomerular filtration rate\<60 ml/min/1.73m2 within 90 days
- • 9. Body mass index \>35kg/m2
- • 10. Expressing a clear preference for undergoing CIT or not
- • 11. Pregnancy
Trial Officials
Jia Zhou, MD
Principal Investigator
Tianjin Chest Hospital
About Tianjin Chest Hospital
Tianjin Chest Hospital is a leading medical institution in China, specializing in respiratory diseases and thoracic surgery. With a strong commitment to advancing healthcare through research and innovation, the hospital conducts clinical trials aimed at improving patient outcomes and developing new treatment modalities. Equipped with state-of-the-art facilities and a dedicated team of healthcare professionals, Tianjin Chest Hospital plays a pivotal role in translating clinical research into practice, fostering collaboration between academia and industry to enhance therapeutic options for patients with respiratory conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Tianjin, , China
Tianjin, Tianjin, China
Lanfang, Hebei, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials